Differential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists

Journal of Neurochemistry

Volumn 95, Issue 6, 2005, Pages 1575-1584

  Parrish, Jason C ^a   Braden, Michael R ^a   Gundy, Emily ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

5 HT2A; Hallucinogen; Phenethylamine; Phenylisopropylamine; Phospholipase C; Serotonin

Indexed keywords

PHENYLALKYLAMINE; PHENYLISOPROPYLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PROPYLAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYDROLYSIS; LIGAND BINDING; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR POTENTIAL; SEROTONIN RELEASE; STEREOCHEMISTRY; THREE DIMENSIONAL IMAGING;

ANIMALS; CATTLE; CELL LINE; COMPUTER SIMULATION; ENZYME ACTIVATION; HALLUCINOGENS; HUMANS; HYDROLYSIS; INOSITOL PHOSPHATES; MODELS, MOLECULAR; PHENETHYLAMINES; PHOSPHOLIPASE C; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29144460257     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03477.x     Document Type: Article

References (45)

1. Acuna-Castillo C., Villalobos C., Moya P. R., Saez P., Cassels B. K. and Huidobro-Toro J. P. (2002) Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT (2A) and 5-HT (2C) receptors. Br. J. Pharmacol. 136, 510-519.
2. Almaula N., Ebersole B. J., Zhang D., Weinstein H. and Sealfon S. C. (1996) Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36 (159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J. Biol. Chem. 271, 14 672-14 675.
3. Ballesteros J. A. and Weinstein H. (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptor. Meth. Neurosci. 25, 366-428.
4. Bluml K., Mutschler E. and Wess J. (1994) Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J. Biol. Chem. 269, 18 870-18 876.
5. Chambers J. J. and Nichols D. E. (2002) A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. J. Comput. Aided Mol. Des. 16, 511-520.
6. Chambers J. J., Parrish J. C., Jensen N. H., Kurrasch-Orbaugh D. M., Marona-Lewicka D. and Nichols D. E. (2003) Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT2A/2C receptor ligands. J. Med. Chem. 46, 3526-3535.
7. Cheng H. C., Long J. P., Nichols D. E. and Barfknecht C. F. (1974) Effects of psychotomimetics on vascular strips: studies of methoxylated amphetamines and optical isomers of 2,5-dimethoxy-4-methylamphetamine and 2,5-dimethoxy-4-bromoamphetamine. J. Pharmacol. Exp. Ther. 188, 114-123.
8. Choudhary M. S., Craigo S. and Roth B. L. (1993) A single point mutation (Phe340 → Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy) phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxy-tryptamine2 receptors. Mol. Pharmacol. 43, 755-761.
9. DeLano W. L. (2002) The PyMOL Molecular Graphics System, http://www.pymol.org. Ref Type: Electronic Citation.
10. Dyer D. C., Nichols D. E., Rusterholz D. B. and Barfknecht C. F. (1973) Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines. Life Sci. 13, 885-896.
11. Farrens D. L., Altenbach C., Yang K., Hubbell W. L. and Khorana H. G. (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274, 768-770.
12. Gelber E. I., Kroeze W. K., Willins D. L., Gray J. A., Sinar C. A., Hyde E. G., Gurevich V., Benovic J. and Roth B. L. (1999) Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purified arrestins. J. Neurochem. 72, 2206-2214.
13. Glennon R. A., Young R. and Jacyno J. M. (1983) Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity. Biochem. Pharmacol. 32, 1267-1273.
14. Glennon R. A., Teitler M. and Sanders-Bush E. (1992) Hallucinogens and serotonergic mechanisms. NIDA Res. Monogr. 119, 131-135.
15. Harris R. A., Snell D. and Loh H. H. (1977) Stereoselective effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) on schedule-controlled behavior. Pharmacol. Biochem. Behav. 1, 307-310.
16. Heffter A. (1898) Ueber pellote. Beitrag zur chemischen und pharmakologischen kenntnis der cacteen. Naunyn Schmiedebergs Arch. Exp. Path. Pharmacol. 40, 385-429.
17. Heitz F., Holzwarth J. A., Gies J. P., Pruss R. M., Trumpp-Kallmeyer S., Hibert M. F. and Guenet C. (1999) Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. Eur. J. Pharmacol. 380, 183-195.
18. Hey P. (1947) The synthesis of a new homolog of mescaline. Quart. J. Pharm. Pharmacol. 20, 129-134.
19. Hill-Eubanks D., Burstein E. S., Spalding T. A., Brauner-Osborne H. and Brann M. R. (1996) Structure of a G-protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis. J. Biol. Chem. 271, 3058-3065.
20. Huang X. P., Nagy P. I., Williams F. E., Peseckis S. M. and Messer W. S. Jr (1999) Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors. Br. J. Pharmacol. 126, 735-745.
21. Jacob J. N. and Nichols D. E. (1982) Isomeric cyclopropyl ring-methylated homologues of trans-2-(2,5-dimethoxy-4-methylphenyl) cyclopropylamine, an hallucinogen analogue. J. Med. Chem. 25, 526-530.
22. Johnson M. P., Hoffman A. J., Nichols D. E. and Mathis C. A. (1987) Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI. Neuropharmacology 26, 1803-1806.
23. Johnson M. P., Mathis C. A., Shulgin A. T., Hoffman A. J. and Nichols D. E. (1990) [125I]-2-(2,5-dimethoxy-4-iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol. Biochem. Behav. 35, 211-217.
24. Johnson M. P., Audia J. E., Nissen J. S. and Nelson D. L. (1993) N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor. Eur. J. Pharmacol. 239, 111-118.
25. Johnson M. P., Wainscott D. B., Lucaites V. L., Baez M. and Nelson D. L. (1997) Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner. Brain Res. Mol. Brain Res. 49, 1-6.
26. Kristiansen K., Kroeze W. K., Willins D. L., Gelber E. I., Savage J. E., Glennon R. A. and Roth B. L. (2000) A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT (2A) serotonin receptor but does not participate in activation via a 'salt-bridge disruption' mechanism. J. Pharmacol. Exp. Ther 293, 735-746.
27. Kurrasch-Orbaugh D. M., Watts V. J., Barker E. L. and Nichols D. E. (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J. Pharmacol. Exp. Ther. 304, 229-237.
28. Nash J. F., Roth B. L., Brodkin J. D., Nichols D. E. and Gudelsky G. A. (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci. Lett. 177, 111-115.
29. Nichols D. E. (2004) Hallucinogens. Pharmacol. Ther. 101, 131-181.
30. Nichols D. E., Barfknecht C. F., Rusterholz D. B., Benington F. and Morin R. D. (1973) Asymmetric synthesis of psychotomimetic phenylisopropylamines. J. Med. Chem. 16, 480-483.
31. Nichols D. E., Frescas S., Marona-Lewicka D., Huang X., Roth B. L., Gudelsky G. A. and Nash J. F. (1994) 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl) -2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J. Med. Chem. 37, 4346-4351.
32. Oksenberg D., Havlik S., Peroutka S. J. and Ashkenazi A. (1995) The third intracellular loop of the 5-hydroxytryptamine2A receptor determines effector coupling specificity. J. Neurochem. 64, 1440-1447.
33. Perrine D. M. (2001) Visions of the night: Western medicine meets peyote 1887-1899. Heffter Rev. 2, 6-52.
34. Roth B. L., Shoham M., Choudhary M. S. and Khan N. (1997) Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Mol. Pharmacol. 52, 259-266.
35. Shapiro D. A., Kristiansen K., Kroeze W. K. and Roth B. L. (2000) Differential modes of agonist binding to 5-hydroxytryptamine (2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol. Pharmacol. 58, 877-886.
36. Shulgin A. T. (1973) Mescaline: the chemistry and pharmacology of its analogs. Lloydia 36, 46-58.
37. Shulgin A. and Shulgin A. (1991) PIHKAL. A Chemical Love Story. Transform Press, Berkeley, CA.
38. Shulgin A. T., Bunnell S. and Sargent T. (1961) The psychotomimetic properties of 3,4,5-trimethoxyamphetamine. Nature 189, 1011-1012.
39. Suel G. M., Lockless S. W., Wall M. A. and Ranganathan R. (2003) Evolutionary conserved networks of residues mediate allosteric communication in proteins. Nat. Struct. Biol. 10, 59-69.
40. Villalobos C. A., Bull, P., Saez P., Cassels B. K. and Huidobro-Toro J. P. (2004) 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol. 141, 1167-1174.
41. Vollenweider F. X., Vollenweider-Scherpenhuyzen M. F., Babler A., Vogel H. and Hell D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897-3902.
42. Wang C. D., Gallaher T. K. and Shih J. C. (1993) Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Mol. Pharmacol. 43, 931-940.
43. Ward S. D., Curtis C. A. and Hulme E. C. (1999) Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. Mol. Pharmacol. 56, 1031-1041.
44. Wieland K., Laak A. M., Smit M. J., Kuhne R., Timmerman H. and Leurs R. (1999) Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J. Biol. Chem. 274, 29 994-30 000.
45. Young R. and Glennon R. A. (1996) A three-lever operant procedure differentiates the stimulus effects of R. (-)-MDA from S (+)-MDA. J. Pharmacol. Exp. Ther 276, 594-601.